Syracuse

Using medical exome sequencing to identify the causes of neurodevelopmental disorders: Experience of 2 clinical units and 216 patients

Archive ouverte

Chérot, E | Keren, B | Dubourg, C | Carré, W | Fradin, M | Lavillaureix, A | Afenjar, A | Burglen, L | Whalen, S | Charles, P | Marey, I | Heide, S | Jacquette, A | Heron, D | Doummar, D | Rodriguez, D | Billette de Villemeur, T | Moutard, M-L | Guët, A | Xavier, J | Périsse, D | Cohen, David | Demurger, F | Quélin, C | Depienne, C | Odent, S | Nava, C | David, V | Pasquier, L | Mignot, C

Edité par CCSD ; Wiley -

International audience. Although whole-exome sequencing (WES) is the gold standard for the diagnosis of neurodevelopmental disorders (NDDs), it remains expensive for some genetic centers. Commercialized panels comprising all OMIM-referenced genes called "medical exome" (ME) constitute an alternative strategy to WES, but its efficiency is poorly known. In this study, we report the experience of 2 clinical genetic centers using ME for diagnosis of NDDs. We recruited 216 consecutive index patients with NDDs in 2 French genetic centers, corresponded to the daily practice of the units and included non-syndromic intellectual disability (NSID, n = 33), syndromic ID (NSID = 122), pediatric neurodegenerative disorders (n = 7) and autism spectrum disorder (ASD, n = 54). We sequenced samples from probands and their parents (when available) with the Illumina TruSight One sequencing kit. We found pathogenic or likely pathogenic variants in 56 index patients, for a global diagnostic yield of 25.9%. The diagnosis yield was higher in patients with ID as the main diagnosis (32%) than in patients with ASD (3.7%). Our results suggest that the use of ME is a valuable strategy for patients with ID when WES cannot be used as a routine diagnosis tool.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion